Hyun Jae Kim

Hyun Jae Kim

Auto-generated profile, based on publicly available information

Hyun Jae Kim

Neudive Inc, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
ELEnn Young Lee
Enn Young Lee
SCSungJa Cho
SungJa Cho
RJRan Ju
Ran Ju
HKHyunjae Kim
Hyunjae Kim
TCTae Young Choi
Tae Young Choi
YJYoo-Sook Joung
Yoo-Sook Joung
Background: Autism spectrum disorder (ASD) and social communication disorder (SCD) are neurodevelopmental disorders characterized by deficits in social communication that hinder social adaptation, with limited pharmacological options for therapy owing to the absence of identified biomarkers. Individuals with ASD or SCD require lifelong interventions tailored to their development stages. However, most existing interventions primarily focus on early childhood, leaving adolescents relatively underserved. Moreover, timely access to interventions is often limited by geographic and economic barriers as specialized clinics and therapists tend to be concentrated in major urban areas. Objective: This pilot randomized clinical trial aimed to evaluate the initial safety and efficacy of NDTx-01, a digital therapeutic (DTx) for adolescents with ASD or SCD. NDTx-01 was designed to overcome the accessibility limitations by integrating cognitive behavioral therapy principles, story-based interventions, and gamification elements. Methods: We introduce a protocol for a multicenter, prospective, assessor-blinded pilot randomized clinical trial involving children and adolescents aged 10 to 18 years diagnosed with ASD or SCD. Participant enrollment was conducted at 3 major medical hospitals. Enrolled participants were randomly assigned to either the intervention group (NDTx-01 and treatment as usual [TAU]) or the control group (TAU only). TAU included medications and therapeutic services. Participants were instructed to use the app approximately 10 minutes per day, 5 days a week. To evaluate the efficacy of NDTx-01, standardized tools were administered, including the Korean version of the Vineland Adaptive Behavior Scales, Second Edition (K-VABS-II); the Social Responsiveness Scale, Second Edition; Clinical Global Impressions–Severity (CGI-S); Clinical Global Impressions–Improvement (CGI-I); the Social Communication Questionnaire; and the Korean version of the Stress Index for Parents of Adolescents. Assessments were conducted in weeks 0, 1, 2, 4, and 6, except for K-VABS-II, CGI-S, and CGI-I, which were administered only in weeks 0, 4, and 6. Statistical analyses were conducted using the SAS software. Between-group differences were assessed using independent 2-tailed 2-sample t tests or Wilcoxon rank sum tests. Within-group changes were evaluated using paired t tests or Wilcoxon signed rank tests. Results: From August 2024 to December 2024, a total of 42 individuals were screened, 39 (93%) participants who met the inclusion criteria were enrolled, and 1 participant withdrew consent; the remaining participants completed the study. The pilot randomized clinical trial was successfully completed, and the results were published in April 2025. As of 2025, we are conducting a confirmatory clinical trial at 5 major hospitals across South Korea. Conclusions: The results of this pilot clinical trial provided important insights into the initial safety and efficacy of DTx as interventions for adolescents with ASD and SCD. Both groups demonstrated statistically significant improvements in adaptive skills and socialization. Trial Registration: Clinical Research Information Service KCT0009140; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=26713 International Registered Report Identifier (IRRID): DERR1-10.2196/66419

14 September 2024 in JMIR Preprints
Verified
Preprint
Open access
YJYoo-Sook Joung
Yoo-Sook Joung
ELEnn Young Lee
Enn Young Lee
SCSung Ja Cho
Sung Ja Cho
RJRan Ju
Ran Ju
HKHyun Jae Kim
Hyun Jae Kim
JYJae Hyun Yoo
Jae Hyun Yoo
BACKGROUND Autism spectrum disorder (ASD) and social communication disorder (SCD) are characterized by deficits in social communication that hinder social adaptation, with limited pharmacologic options for therapy due to the absence of identified biomarkers. OBJECTIVE Recognizing the need for accessible and cost-effective interventions, we developed the digital therapeutic NDTx-01, integrating cognitive behavioral therapy principles, story-based interventions, and gamification elements. METHODS This study introduces a protocol for evaluating the efficacy and safety of NDTx-01 through a multicenter, prospective, randomized, assessor-blinded pilot trial involving adolescents aged 1018 years. Participant recruitment and enrollment will be executed in three major medical hospitals, where inter-reliability will be managed by the study team. Enrolled participants, divided into intervention and control groups, will undergo a 6-week intervention with NDTx-01 and usual care or maintain usual care, respectively. The intervention, implemented by NDTx-01, will be structured to last for 6 weeks, with sessions of approximately 10 minutes daily, 5 days a week. Following this, data analysis, including frequency analysis, descriptive statistical analysis, and tests for within-group and between-group differences, will be undertaken. RESULTS As of August 2024, we enrolled 39 patients, and this clinical trial has been successfully completed. CONCLUSIONS Anticipated results, to be published in April 2024, aim to contribute crucial insights into the effectiveness of digital therapeutics as interventions for ASD and SCD in adolescents.